NSE: MEDANTA · 4 November 2026
- Global Health has risen 10.37% over 3 trading sessions; today's move is +5.75%.
- The board of directors approved a project budget of ₹997 crores, which includes the cost of land, for the construction of a 500-bed super-specialty hospital. The facility is planned on a free-hold land parcel measuring 10,560.36 square meters located at Siddharth Vihar Yojna, Ghaziabad, Uttar Pradesh, allotted by the UP Housing & Development Board.
- Trading volume was 11.16 times the 20-day average daily volume.
Global Health share price: 10.37% rise over 3 trading sessions
Global Health Ltd. (MEDANTA) advanced by 5.75% today, closing at ₹1,402.0 after trading between an intraday low of ₹1,326.6 and a high of ₹1,423.6. The session opened at ₹1,374.5, reflecting a gap-up of 3.67% over the previous close of ₹1,325.8.
The broader market and sectoral benchmarks posted positive returns during the session, with the Nifty rising by 0.63% and the Nifty Pharma sector index gaining 0.42%. Against this backdrop, the stock outperformed both the wider market and its sector benchmark. Over the preceding moving windows, the stock registered a 5-day return of 9.28% and a 20-day return of 7.78%, extending an ongoing period of upward momentum.
Company disclosures provide ongoing fundamental context as the board recently approved a project budget of ₹997 crores for a 500-bed super-specialty hospital in Ghaziabad, following the acquisition of a 10,560.36 square metre land parcel. Furthermore, financial reporting for the second quarter and half-year ended September 30, 2026, highlighted a 33.6% year-on-year growth in operating revenue to ₹14,690 million alongside a 60.2% increase in operating EBITDA to ₹3,701 million.
23.79 lakh shares traded by 4 November 2026 · 03:30 PM IST. This compares with a 20-day average daily volume of 2.13 lakh shares (11.16 times). The five-day average daily volume was 2.05 lakh shares. Separately, the NSE report for 4 November 2026 showed 7.50 lakh shares delivered, representing 31.51% of that day’s traded volume. The same report recorded 148,823 trades.
The stock's upward movement aligns with positive market reception of the recently announced second-quarter financial results, showing robust revenue and EBITDA growth, alongside ongoing updates regarding network capacity expansion in Ghaziabad.
Latest Company Developments
The board of directors approved a project budget of ₹997 crores, which includes the cost of land, for the construction of a 500-bed super-specialty hospital. The facility is planned on a free-hold land parcel measuring 10,560.36 square meters located at Siddharth Vihar Yojna, Ghaziabad, Uttar Pradesh, allotted by the UP Housing & Development Board.
It marks a key execution step in expanding the company's multi-specialty healthcare footprint into new regional markets.
The company reported consolidated revenue from operations of ₹14,690 million for the second quarter ended September 30, 2026, marking a 33.6% year-on-year increase. Operating EBITDA grew 60.2% to ₹3,701 million with margins improving to 25.2%, while profit after tax stood at ₹2,191 million compared to ₹1,584 million in the corresponding previous quarter.
Strong operational volume growth and margin expansion across hospital clusters underpin the company's financial performance.
Dr. Pankaj Dhamija ceased to hold the position of Hospital Director for the Gurugram Unit and designated Senior Management Personnel of the company, effective October 30, 2026. The filing was submitted to stock exchanges as part of routine corporate governance updates.
Management and operational leadership transitions provide context on internal organizational changes.
a press release dated November 03, 2026, titled "Press release for the Results of Second Quarter & Half Year ended September 30, 2026."
Global Health Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 15.97% on 30 September 2026. This compares with 16.03% on 30 June 2026, a change of -0.06 percentage points.
The filing reported 30 MF/UTI holders.
Research & Brokerage Views
Investec initiated coverage with a Buy rating, noting that Medanta added 47% more beds while inpatient occupancy continued to rise across its network.
Historical Bulk / Block Deals
What to Watch Next
- Execution and construction timelines for the newly approved 500-bed super-specialty hospital project in Ghaziabad
- Ramp-up in occupancy rates and operational metrics for recently added bed capacity in Noida and Lucknow
- Quarterly inpatient and outpatient volume trends across Cluster 1 and Cluster 2 hospital networks
- Sustained delivery percentage and cash volume participation relative to the 20-day average volume
Other Dated Coverage
- Global Health Share Price Today: Why MEDANTA Is Rising 2.21% | 2 November 2026 — 2 November 2026
- Global Health Share Price Today: Why MEDANTA Is Rising 4.01% | 27 October 2026 — 27 October 2026
More Global Health news and dated analysis →
Frequently Asked Questions
What is the latest Global Health company news?
The board of directors approved a project budget of ₹997 crores, which includes the cost of land, for the construction of a 500-bed super-specialty hospital. The facility is planned on a free-hold land parcel measuring 10,560.36 square meters located at Siddharth Vihar Yojna, Ghaziabad, Uttar Pradesh, allotted by the UP Housing & Development Board.
How strong was Global Health’s trading volume?
23.79 lakh shares traded, 11.16 times the 20-day average daily volume. The price and volume data are dated 4 November 2026 · 03:30 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.